LiveClin: A Live Clinical Benchmark without Leakage
Organizations: The Chinese University of Hong Kong, ShenZhen · Ant Healthcare, Ant Group · The Ohio State University · Zhejiang University
Abstract
The reliability of medical LLM evaluation is critically undermined by data contamination and knowledge obsolescence, leading to inflated scores on static benchmarks. To address these challenges, we introduce LiveClin, a live benchmark designed for approximating real-world clinical practice. Built from contemporary, peer-reviewed case reports and updated biannually, LiveClin ensures clinical currency and resists data contamination. Using a verified AI-human workflow involving 239 physicians, we transform authentic patient cases into complex, multimodal evaluation scenarios that span the entire clinical pathway. The benchmark currently comprises 1,407 case reports and 6,605 questions. Our evaluation of 26 models on LiveClin reveals the profound difficulty of these real-world scenarios, with the top-performing model achieving a Case Accuracy of just 35.7%. In benchmarking against human experts, Chief Physicians achieved the highest accuracy, followed closely by Attending Physicians, with both surpassing most models. LiveClin thus provides a continuously evolving, clinically grounded framework to guide the development of medical LLMs towards closing this gap and achieving greater reliability and real-world utility. Our data and code are publicly available at https://github.com/AQ-MedAI/LiveClin.
Figures & tables
| Method | Accuracy (%) | Trivial Ratio (%) | Time (hrs) † | Cost ($) |
| Physicians | 92.5 | 38.5 | 188.9 | 4534.30 |
| Generator | 84.5 | 16.5 | 0.13 | 35.34 |
| Generator-Critic | 93.0 | 5.5 | 0.45 | 221.69 |
| Generator-Critic-Judge | 89.5 * | 5.5 | 0.55 | 244.19 |
| Stage I | Stage II | Stage III | Evaluation | Total (Cost/Time) |
| 0 / 0.8 | 3,500 / 0.5 | 45,000 / 9.0 | 5,000 / 1.0 | 53,500 / 11.3 |
| Time | GPT-5 | GPT-4.1 | InternVL 3.5-24B | Gemini 2.5 Pro | Claude 3.5 Sonnet | Qwen2.5-VL-72B | MedGemma-27B | LingShu-32B | HuatuoGPT-V-7B |
| H1 2025 | 35.5 | 31.8 | 34.4 | 33.7 | 27.3 | 17.2 | 15.6 | 20.1 | 9.2 |
| July 2025 | 36.8 | 33.2 | 35.8 | 35.1 | 28.7 | 18.6 | 16.9 | 21.4 | 10.5 |
| Aug 2025 | 34.1 | 30.4 | 33.0 | 32.3 | 26.0 | 15.8 | 14.2 | 18.7 | 8.0 |
Appendix figures & tables22 assets
Supplementary material from the paper’s appendix.
Appendix
| ICD-10 Chapters (Level 1) | Disease Clusters (Level 2) |
| §1: Infectious & Parasitic | Intestinal Inf. & Tuberculosis (A00-19); Zoonotic bacterial (A20-28); Bacterial, Spirochetal, Chlamydial Inf., etc. (A30-79); Viral Inf. (CNS, HIV, etc.) (A80-B34); Fungal & Protozoal Inf. (B35-64); Parasitic & Helminthic (B65-98) |
| §2: Neoplasms | Malignant Neoplasms of Lip, Oral, Pharynx (C00-14); Digestive Organs (C15-26); Respiratory & Intrathoracic (C30-39); Bone & Cartilage (C40-41); Skin (C43-44); Mesothelial & Soft Tissue (C45-49); Breast (C50); Female Genital Organs (C51-58); Male Genital Organs (C60-63); Urinary Tract (C64-68); Eye, Brain & CNS (C69-72); Thyroid & Endocrine (C73-75); Lymphoid Tissues (C76-96); Benign, In Situ. (C97, D00-48) |
| §3: Blood, Blood-forming Organs & Immune Mechanism | Nutr, Hemol& Aplast Anemias (D50-64); Coagulation Defects, Purpura & Hemorrhagic Cond. (D65-69); Blood-Forming Organ (D70-77); Immune Mechanism Disord. (D80-89) |
| §4: Endocrine, Nutritional & Metabolic | Thyroid Disorders. (E00-07); Diabetes mellitus (E10-14); Endocrine, Glucose Reg. & Nutritional Deficiencies (E15-64); Obesity & Metabolic Disorders (E65-90) |
| §5: Mental & Behavioural Disord. | Comprehensive Mental & Behavioural Disord. (F00-98) |
| §6: Nervous System | Inflammatory & systemic atrophic of CNS (G00-14); Extrapyramidal, Movement, & Degen. Disord. (G20-32); Demyelinating of CNS (G35-37); Episodic & paroxysmal disord. (G40-47); Nerve root & plexus disord. (G50-59); Polyneuropathies & other PNS disord. (G60-64); Muscle, Myoneural, & Paralytic Disord. (G70-99) |
| Loop 1 | Loop 2 | Loop 3 | |
| Case Num | 1286 (91.4%) | 109 (7.8%) | 12 (0.9%) |
| Major Specialty (Total, %) | Subspecialty | Count |
| Internal Medicine (95, 39.8%) | Cardiology | 8 |
| Nephrology | 4 | |
| Gastroenterology | 7 | |
| Respiratory Medicine | 5 | |
| Hematology | 5 | |
| Endocrinology | 3 |
| Clinical Pathway Stage | 0–20% | 20–40% | 40–60% | 60–80% | 80–100% |
| Proportion | 62.0% | 46.0% | 35.5% | 27.5% | 38.5% |
| Major Specialty | Subspecialty | Count |
| Internal Medicine (31) | Cardiology | 3 |
| Nephrology | 1 | |
| Gastroenterology | 2 | |
| Respiratory Medicine | 2 | |
| Hematology | 2 | |
| Endocrinology | 1 |
| Model | Run 1 (%) | Run 2 (%) | Run 3 (%) | Std. Dev. |
| GPT-5 | 35.5 | 35.4 | 35.6 | 0.22 |
| o3 | 35.7 | 35.2 | 35.9 | 0.36 |
| GPT-4.1 | 31.8 | 31.7 | 31.9 | 0.10 |
| GPT-4.1-mini | 26.1 | 26.0 | 26.1 | 0.00 |
| GPT-4o | 14.7 | 14.7 | 14.8 | 0.12 |
| GPT-4o-mini | 14.8 | 14.8 | 14.9 | 0.08 |
| Model | Zero-shot (%) | One-shot (%) | Three-shot (%) |
| GPT-5 | 35.5 | 35.8 (+0.3) | 35.1 (-0.4) |
| GPT-4.1 | 31.8 | 31.5 (-0.3) | 32.3 (+0.5) |
| InternVL 3.5-24B | 34.4 | 34.7 (+0.3) | 34.9 (+0.5) |
| Gemini-2.5 Pro | 33.7 | 33.1 (-0.6) | 32.9 (-0.8) |
| Claude-3.5 Sonnet | 27.3 | 27.0 (-0.3) | 27.9 (+0.6) |
| Qwen2.5-VL-72B | 17.2 | 17.4 (+0.2) | 17.0 (-0.2) |
| Loop Num | 1 | 2 | 3 |
| Case Number (Proportion) | 1276 (90.7%) | 113 (8.0%) | 18 (1.1%) |
| Model | Rare (%) | Unrare (%) | Overall (%) | |
| GPT-5 | 35.65 | 35.05 | -0.60 | 35.5 |
| O3 | 35.99 | 34.11 | -1.88 | 35.7 |
| GPT-4.1 | 31.92 | 30.84 | -1.08 | 31.8 |
| GPT-4.1-mini | 26.32 | 25.00 | -1.32 | 26.1 |
| GPT-4o | 14.23 | 17.76 | 3.53 | 14.7 |
| GPT-4o-mini | 14.15 | 19.34 | 5.19 | 14.8 |
Clinical Language Model Evaluation
Clinical language model evaluation measures whether AI systems are accurate, safe, fair, and useful across medical tasks and care settings.
See all 418 papers